---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-224139"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T01:59:20.260499+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026

## Summary
- Reaffirms ~$4B total revenues in 2027.
- Non-GAAP operating margin of 40% starting in 2026, growing to low- to mid-40% range.
- Targets >$1.25B operating cash flow per year starting in 2027.
- Mid-teen CAGR for total revenues through 2034.
- Potential treatments for skeletal conditions represent >$5B revenue opportunity.

## SEC filing metadata
- accession: 0001193125-24-224139
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/0001193125-24-224139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/d887671d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-224139
- JSON: https://secwatch.observer/filing/0001193125-24-224139.json
- Plain text: https://secwatch.observer/filing/0001193125-24-224139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.